Abstract Search

ea0026p86 | Endocrine tumours and neoplasia | ECE2011

Role of peptide receptor radionuclide therapy (PRRT) in well and moderately differentiated neuroendocrine tumours

Bianchi A , Milardi D , Iacovazzo D , Tartaglione L , Grande G , Piacentini S , Pontecorvi A , De Marinis L

PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than SSA. We investigated the role of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours. We evaluated 55 patients with well or moderately differentiated neuroendocrine tumours; 31 patients with either metastatic, unresectable or functioning tumours were ...

0 shares

ea0029p820 | Endocrine tumours and neoplasia | ICEECE2012

Medical and Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Well and Moderately Differentiated Neuroendocrine Tumours

Bianchi A. , Iacovazzo D. , Lugli F. , Fusco A. , Chiloiro S. , Mormando M. , Tartaglione L. , Grande G. , Larghi A. , Schinzari G. , Doglietto G. , Margaritora S. , Perotti G. , Rindi G. , Pontecorvi A. , De Marinis L.

Introduction: Peptide receptor radionuclide therapy (PRRT) is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than somatostatin analogues (SSA).Aims: To demonstrate the efficacy of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours.Materials and methods: We evaluat...

0 shares

Endocrine Abstracts

Role of peptide receptor radionuclide therapy (PRRT) in well and moderately differentiated neuroendocrine tumours

Medical and Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Well and Moderately Differentiated Neuroendocrine Tumours

BiosciAbstracts